Qβ-pT181-immunized mice exhibited robust antibody responses, reduction in tau pathology, neuroinflammation, neurodegeneration and cognitive decline.29 However, tau protein can be differentially phosphorylated in AD and at different disease stages,33 therefore, it is possible that vaccines targeting a single epitope may be inadequate to modify the disease process for all patients at all disease stages. This evidence concerns the gene MAPT and Alzheimer disease.